Literature DB >> 31744551

The IES-R remains a core outcome measure for PTSD in critical illness survivorship research.

Megan M Hosey1,2, O Joseph Bienvenu2,3, Victor D Dinglas2,4, Alison E Turnbull2,5,6, Ann M Parker2,4, Ramona O Hopkins7,8, Karin J Neufeld2,3, Dale M Needham9,10,11.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31744551      PMCID: PMC6865007          DOI: 10.1186/s13054-019-2630-3

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
To the Editor: In response to Dr. Umberger’s comments [1] on the Impact of Event Scale-Revised (IES-R) [2] and the abbreviated 6-item IES (IES-6) [3], we offer guidance about assessing post-traumatic stress disorder (PTSD) symptoms as part of the existing National Institutes of Health-funded core outcome measurement set (COMS) for clinical research in acute respiratory failure (ARF) survivors [4]. An originator of the IES-R is no longer distributing the IES-R because PTSD diagnostic criteria have been revised in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM–5) [1]. Compared to DSM-IV, the DSM-5 separated the avoidance and numbing criteria and increased the number of associated symptoms from 17 to 20 [5]. However, this revision does not fundamentally change the phenotype of PTSD, and the IES-R/IES-6 continues to have utility in screening for PTSD symptoms [3, 5]. With respect to the above mentioned COMS, existing research has been highly heterogeneous in assessing PTSD, thus limiting advances in the field [4]. A 77-member international modified Delphi expert panel evaluated commonly used PTSD measures based on many criteria, including available psychometric evidence in ARF survivors, with a clear consensus recommendation to use the IES-R [4]. Diagnostic criteria for psychiatric disorders change frequently, without fundamental changes to the phenotype. Hence, without rigorous new research on PTSD screening in ARF survivors and another international consensus process, we do not endorse a unilateral change to the PTSD symptom measure recommended within the existing COMS (more information on the COMS is available at www.improveLTO.com). In our communication with an originator of the IES-R regarding the above issues, his responses were “I consider it [IES-R] out of copyright …” and “There are enough [IES-R] copies floating around that you can more or less do whatever you want.” (Daniel S. Weiss, September 4, 2019) As evidence supporting the latter comment, we provide exemplar websites and publications that share the IES-R instrument (Table 1).
Table 1

Information on the Impact of Events Scale-Revised (IES-R) and IES-6 items and scoring

InstrumentSourceAccess information
IES-RPublicationWeiss DS, Marmar CR. The impact of event scale – revised. In Assessing Psychological Trauma and PTSD. 1997, 399–411. (page 408, Chapter 13*)
Douglas Mental Health Institute and McGill Universityhttp://www.info-trauma.org/flash/media-e/diagnosisToolkit.pdf (page 6 of pdf*)
New York University Rory Meyers College of Nursinghttps://consultgeri.org/try-this/general-assessment/issue-19.pdf (page 2 of pdf*)
PublicationBeck JG, et al. The impact of event scale-revised: psychometric properties in a sample of motor vehicle survivors. Journal of Anxiety Disorders, 2008;22 (2) 187–198.
IES-6-itemPublicationHosey et al. Screening for posttraumatic stress disorder in ARDS survivors: validation of the Impact of Event Scale-6 (IES-6). Critical Care, 2019; 23 (1), 1–7. https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2553-z

*Recommended approach for scoring IES-R based on existing IES-R psychometric publication in acute respiratory failure survivors (Bienvenu OJ, et al. Posttraumatic stress disorder in survivors of acute lung injury: evaluating the Impact of Event Scale-Revised. Chest, 2013; 144 (1), 24–31.) and Dr. Daniel S. Weiss (personal communication June 20, 2014):

 • To obtain the three subscale scores (avoidance, hyperarousal, intrusion): calculate the mean of the subscale items

 • To obtain a total score: calculate the mean of all non-missing items in the instrument

 • IES-6-item is scored as mean value for these six items from IES-R

Information on the Impact of Events Scale-Revised (IES-R) and IES-6 items and scoring *Recommended approach for scoring IES-R based on existing IES-R psychometric publication in acute respiratory failure survivors (Bienvenu OJ, et al. Posttraumatic stress disorder in survivors of acute lung injury: evaluating the Impact of Event Scale-Revised. Chest, 2013; 144 (1), 24–31.) and Dr. Daniel S. Weiss (personal communication June 20, 2014): • To obtain the three subscale scores (avoidance, hyperarousal, intrusion): calculate the mean of the subscale items • To obtain a total score: calculate the mean of all non-missing items in the instrument • IES-6-item is scored as mean value for these six items from IES-R We hope that this information may provide helpful clarification in screening for PTSD symptoms in ARF survivors, a task that is essential for improving survivorship outcomes.
  5 in total

1.  Diagnostic and statistical manual of mental disorders, fifth edition, and the impact of events scale-revised.

Authors:  Sundar Gnanavel; Ruby Stella Robert
Journal:  Chest       Date:  2013-12       Impact factor: 9.410

2.  Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study.

Authors:  Dale M Needham; Kristin A Sepulveda; Victor D Dinglas; Caroline M Chessare; Lisa Aronson Friedman; Clifton O Bingham; Alison E Turnbull
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

3.  Posttraumatic stress disorder in survivors of acute lung injury: evaluating the Impact of Event Scale-Revised.

Authors:  O Joseph Bienvenu; Jason B Williams; Andrew Yang; Ramona O Hopkins; Dale M Needham
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

4.  Screening for posttraumatic stress disorder in ARDS survivors: validation of the Impact of Event Scale-6 (IES-6).

Authors:  Megan M Hosey; Jeannie-Marie S Leoutsakos; Ximin Li; Victor D Dinglas; O Joseph Bienvenu; Ann M Parker; Ramona O Hopkins; Dale M Needham; Karin J Neufeld
Journal:  Crit Care       Date:  2019-08-07       Impact factor: 9.097

5.  What is the best core measure after critical illness when the IES-R is no longer accessible for new researchers?

Authors:  Reba Umberger
Journal:  Crit Care       Date:  2019-09-13       Impact factor: 9.097

  5 in total
  9 in total

1.  The Prevalence of Spiritual and Social Support Needs and Their Association With Postintensive Care Syndrome Symptoms Among Critical Illness Survivors Seen in a Post-ICU Follow-Up Clinic.

Authors:  Tammy L Eaton; Leslie P Scheunemann; Brad W Butcher; Heidi S Donovan; Sheila Alexander; Theodore J Iwashyna
Journal:  Crit Care Explor       Date:  2022-04-08

2.  Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus.

Authors:  Cherica A Tee; Evelyn O Salido; Patrick Wincy C Reyes; Roger C Ho; Michael L Tee
Journal:  Open Access Rheumatol       Date:  2020-09-22

3.  A chain mediation model on COVID-19 symptoms and mental health outcomes in Americans, Asians and Europeans.

Authors:  Cuiyan Wang; Agata Chudzicka-Czupała; Michael L Tee; María Inmaculada López Núñez; Connor Tripp; Mohammad A Fardin; Hina A Habib; Bach X Tran; Katarzyna Adamus; Joseph Anlacan; Marta E Aparicio García; Damian Grabowski; Shahzad Hussain; Men T Hoang; Mateusz Hetnał; Xuan T Le; Wenfang Ma; Hai Q Pham; Patrick Wincy C Reyes; Mahmoud Shirazi; Yilin Tan; Cherica A Tee; Linkang Xu; Ziqi Xu; Giang T Vu; Danqing Zhou; Natalie A Chan; Vipat Kuruchittham; Roger S McIntyre; Cyrus S H Ho; Roger Ho; Samuel F Sears
Journal:  Sci Rep       Date:  2021-03-19       Impact factor: 4.379

4.  Impact on Mental, Physical and Cognitive functioning of a Critical care sTay during the COVID-19 pandemic (IMPACCT COVID-19): protocol for a prospective, multicentre, mixed-methods cohort study.

Authors:  Ana Cristina Castro-Ávila; Catalina Merino-Osorio; Felipe González-Seguel; Agustín Camus-Molina; Jaime Leppe
Journal:  BMJ Open       Date:  2021-09-08       Impact factor: 2.692

5.  Psychological Attachment Orientation and Long-Term Posttraumatic Stress Symptoms Among Family Members of ICU Patients.

Authors:  Qiang Zhang; Andrea K Knies; Jolanta Pach; Tara Kimbrough; Aida Martinez; Prerak Juthani; Stephanie Tu; Joan K Monin; Ana-Maria Vranceanu; David Y Hwang
Journal:  Crit Care Explor       Date:  2022-08-29

6.  Psychological impacts of COVID-19 pandemic in cancer patients on active treatment.

Authors:  Sinan Koca; Esra Koca; Ilker N Okten; Fatma Fc Orengül; Akın Oztürk; Melike Ozçelik; Abdilkerim Oyman; Ibrahim Çil; Mahmut Gümüş
Journal:  Heliyon       Date:  2022-08-18

7.  Facilitating communication for critically ill patients and their family members: Study protocol for two randomized trials implemented in the U.S. and France.

Authors:  J Randall Curtis; Nancy Kentish-Barnes; Lyndia C Brumback; Elizabeth L Nielsen; Kathryn I Pollak; Patsy D Treece; Lisa Hudson; Gigi Garzio; Jennifer Im; Bryan J Weiner; Nita Khandelwal; Matthieu Resche-Rigon; Elie Azoulay; Ruth A Engelberg
Journal:  Contemp Clin Trials       Date:  2021-06-03       Impact factor: 2.261

8.  A longitudinal study on the mental health of general population during the COVID-19 epidemic in China.

Authors:  Cuiyan Wang; Riyu Pan; Xiaoyang Wan; Yilin Tan; Linkang Xu; Roger S McIntyre; Faith N Choo; Bach Tran; Roger Ho; Vijay K Sharma; Cyrus Ho
Journal:  Brain Behav Immun       Date:  2020-04-13       Impact factor: 7.217

9.  The impact of the COVID-19 pandemic on physical and mental health in the two largest economies in the world: a comparison between the United States and China.

Authors:  Cuiyan Wang; Connor Tripp; Samuel F Sears; Linkang Xu; Yilin Tan; Danqing Zhou; Wenfang Ma; Ziqi Xu; Natalie A Chan; Cyrus Ho; Roger Ho
Journal:  J Behav Med       Date:  2021-06-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.